Advanced Medical Isotope Corporation (OTC: ADMD) is engaged in the development of a brachytherapy device for the treatment of cancerous tumors. Brachytherapy uses radiation to destroy tumors by placing a radioactive isotope inside the treatment area. Currently, the company is pursuing FDA approval of its brachytherapy device, RadioGel, initially for the treatment of advanced basal and squamous skin cancers. Concurrently, the Company is pursuing development of veterinary applications for a range of cancers in collaboration with four leading university veterinary hospitals. Veterinary applications should have a faster path to revenue for ADMD, while providing data supporting the safety and therapeutic effectiveness of RadioGel. ADMD’s RadioGel requires no pre-market approval for pet therapy and the Company plans to generate near term revenue from veterinarian clinics and international licensing by 1Q18.